Biodesix (BDSX) Operating Leases (2022 - 2026)

Biodesix has reported Operating Leases for 5 years, with the latest figure at $23.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 3.31% year-over-year to $23.7 million; the trailing twelve-month figure through Mar 2026 stood at $23.7 million (down 3.31% YoY), and the FY2025 full-year result was $24.0 million, down 3.18% from the prior year.
• Operating Leases for Q1 2026 stood at $23.7 million, down from $24.0 million in the prior quarter.
• The five-year high for Operating Leases was $25.5 million in Q2 2024, with the low at $1.2 million in Q1 2022.
• Historically, Operating Leases has averaged $18.5 million across 5 years, with a median of $24.1 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases soared 922.85% — and 2025, when it declined 5.37%.
• Biodesix's Operating Leases stood at $5.3 million in 2022, then surged by 378.93% to $25.2 million in 2023, then decreased by 1.33% to $24.8 million in 2024, then decreased by 3.18% to $24.0 million in 2025, then decreased by 1.54% to $23.7 million in 2026.
• The last three Operating Leases figures came in at $23.7 million (Q1 2026), $24.0 million (Q4 2025), and $24.4 million (Q3 2025), per Business Quant data.